RIGL
NASDAQ · Biotechnology
Rigel Pharmaceuticals Inc
$46.64
+0.79 (+1.72%)
Financial Highlights (FY 2026)
Revenue
292.42M
Net Income
364.70M
Gross Margin
93.3%
Profit Margin
124.7%
Rev Growth
+34.8%
D/E Ratio
0.13
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.3% | 93.3% | 39.5% | 39.5% |
| Operating Margin | 42.6% | 38.4% | -16.5% | -15.8% |
| Profit Margin | 124.7% | 118.5% | -16.5% | -20.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 292.42M | 216.96M | 385.25M | 314.84M |
| Gross Profit | 272.91M | 202.49M | 152.10M | 124.30M |
| Operating Income | 124.66M | 83.24M | -63,385,649 | -49,763,269 |
| Net Income | 364.70M | 243.53M | -63,461,041 | -63,887,744 |
| Gross Margin | 93.3% | 93.3% | 39.5% | 39.5% |
| Operating Margin | 42.6% | 38.4% | -16.5% | -15.8% |
| Profit Margin | 124.7% | 118.5% | -16.5% | -20.3% |
| Rev Growth | +34.8% | +34.8% | +12.7% | +12.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 50.47M | 50.47M | 244.43M | 243.77M |
| Total Equity | 377.77M | 377.77M | 293.70M | 288.30M |
| D/E Ratio | 0.13 | 0.13 | 0.83 | 0.85 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 127.07M | 89.57M | -108,813,206 | -86,400,635 |
| Free Cash Flow | — | — | -71,858,369 | -72,598,863 |